BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18537615)

  • 1. Procarbazine--a traditional drug in the treatment of malignant gliomas.
    Goerne R; Bogdahn U; Hau P
    Curr Med Chem; 2008; 15(14):1376-87. PubMed ID: 18537615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
    Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
    Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 5. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
    Lassman AB
    CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
    BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W; van der Rijt CC; Dinjens WN; Sillevis Smitt PA; Wertenbroek AA; Bromberg JE; van Heuvel I; Kros JM; van den Bent MJ
    J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
    Peyre M; Cartalat-Carel S; Meyronet D; Ricard D; Jouvet A; Pallud J; Mokhtari K; Guyotat J; Jouanneau E; Sunyach MP; Frappaz D; Honnorat J; Ducray F
    Neuro Oncol; 2010 Oct; 12(10):1078-82. PubMed ID: 20488959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
    Shapiro WR; Young DF
    Trans Am Neurol Assoc; 1976; 101():217-20. PubMed ID: 1028239
    [No Abstract]   [Full Text] [Related]  

  • 10. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
    van den Bent MJ
    Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
    Levin VA; Silver P; Hannigan J; Wara WM; Gutin PH; Davis RL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):321-4. PubMed ID: 2154418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
    Gutin PH; Wilson CB; Kumar AR; Boldrey EB; Levin V; Powell M; Enot KJ
    Cancer; 1975 May; 35(5):1398-404. PubMed ID: 1122488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
    Cai Y; Jiang YG; Wang M; Jiang ZH; Tan ZG
    Medicine (Baltimore); 2020 Sep; 99(38):e22238. PubMed ID: 32957367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade gliomas.
    Schiff D
    Continuum (Minneap Minn); 2015 Apr; 21(2 Neuro-oncology):345-54. PubMed ID: 25837900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
    Kaloshi G; Roci E; Rroji A; Ducray F; Petrela M
    J Neurosurg; 2015 Nov; 123(5):1244-6. PubMed ID: 26115464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
    Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
    Baker MJ; Brem S; Daniels S; Sherman B; Phuphanich S
    J Neurooncol; 2002 Sep; 59(3):239-42. PubMed ID: 12241121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
    Mazzocco P; Honnorat J; Ducray F; Ribba B
    Comput Math Methods Med; 2015; 2015():297903. PubMed ID: 26788118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.